The impact of the duration of adjuvant chemotherapy on survival in patients with epithelial ovarian cancer - A retrospective study

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Seebacher, Veronika ^a   Reinthaller, Alexander ^a,b   Koelbl, Heinz ^a   Concin, Nicole ^c   Nehoda, Regina ^c   Polterauer, Stephan ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; THERAPY DELAY; TREATMENT DURATION; UTERINE TUBE CARCINOMA; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 85009227814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169272     Document Type: Article

References (21)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr, accessed on 01/08/2016.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5):1248-59. doi: 10.1200/jco.2002.20.5.1248 PMID: 11870167
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21(17):3194-200. doi: 10. 1200/JCO.2003.02.153 PMID: 12860964
4. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003; 89(Suppl.3):S3-8.
5. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol1. J Clin Oncol 2009; 27(28):4642-8. doi: 10.1200/JCO.2009.21.9691 PMID: 19704064
6. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Group d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009; 115(6):1234-44. doi: 10.1002/cncr.24149 PMID: 19189349
7. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010; 28(34):5061-6. doi: 10.1200/JCO. 2010.29.1351 PMID: 20956625
8. Chen SW, Liang JA, Yang SN, Ko HL, Lin FJ. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 2003; 67(1):69-76. PMID: 12758242
9. Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993; 29A:181-4. PMID: 8422279
10. Fauci JM, Whitworth JM, Schneider KE, Subramaniam A, Zhang B, Frederick PJ, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecologic Oncology 2011; 122(3):532-5. doi: 10.1016/j.ygyno. 2011.05.023 PMID: 21658751
11. Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2013; 129:74-80. doi: 10.1016/j.ygyno. 2012.12.017 PMID: 23262376
12. Anuradha S, Donovan PJ, Webb PM, Brand AH, Goh J, Friedlander M, et al. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer-a population-based study. Acta Oncol 2016; 55(2):226-33. doi: 10.3109/0284186X.2015.1054950 PMID: 26079434
13. Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecologic Oncology 2012; 124(2):221-4. doi: 10.1016/j.ygyno. 2011.10.003 PMID: 22055764
14. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gyaecol Obstet 2000; 70(2):209-62.
15. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000; 36:S11-4. PMID: 10785604
16. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21(8):1431-9. doi: 10.1200/ JCO.2003.09.081 PMID: 12668651
17. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013; 14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2 PMID: 23948349
18. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase-3-trial. Lancet Oncol 2014; 15(4):396-405. doi: 10.1016/S1470-2045(14) 70049-X PMID: 24582486
19. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010; 11(1):75-84. doi: 10.1016/S1470-2045(09)70160-3 PMID: 20129130
20. Gibson SJ, Fleming GF, Temkin SM, Chase DM. The application and outcome of standard of care treatment in elderly women with ovarian cancer: a literature review over the last 10 years. Front Oncol 2016; 24(6):63.
21. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33(28):3199-212. doi: 10.1200/JCO.2015.62.3488 PMID: 26169616